Beta Bionics Overview
Latest ROE for Beta Bionics: -28.46% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-28.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BBNX is -28.46%. That is below the sector sector average of 11.75%. Investors often review this figure alongside Beta Bionics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BBNX currently prints -28.46% for ROE, while the sector average sits near 11.75%. That is roughly 342.2% below the sector mean. Large gaps often invite a closer look at Beta Bionics's growth, margins, and balance sheet.
Return on Equity shows how effectively Beta Bionics converts resources into returns. At -28.46%, BBNX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BBNX's ROE (-28.46%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
